Your browser doesn't support javascript.
loading
Effect of viral storm in patients admitted to intensive care units with severe COVID-19 in Spain: a multicentre, prospective, cohort study.
Bermejo-Martin, Jesús F; García-Mateo, Nadia; Motos, Anna; Resino, Salvador; Tamayo, Luis; Ryan Murua, Pablo; Bustamante-Munguira, Elena; Gallego Curto, Elena; Úbeda-Iglesias, Alejandro; de la Torre, María Del Carmen; Estella, Ángel; Campos-Fernández, Sandra; Martínez Varela, Ignacio; Pérez-García, Felipe; Socias, Lorenzo; López Messa, Juan; Vidal-Cortés, Pablo; Sagredo Meneses, Víctor; González-Rivera, Milagros; Carbonell, Nieves; de Gonzalo-Calvo, David; Martín Delgado, María Cruz; Valdivia, Luis Jorge; Martín-López, Caridad; Jorge García, Ruth Noemí; Maseda, Emilio; Loza-Vázquez, Ana; Kelvin, David J; Barbé, Ferrán; Torres, Antoni.
Afiliación
  • Bermejo-Martin JF; Group for Biomedical Research in Sepsis (BioSepsis), Instituto de Investigación Biomédica de Salamanca, Gerencia Regional de Salud de Castilla y León, Salamanca, Spain; Centro de Investigación Biomédica en Red en Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain; Res
  • García-Mateo N; Group for Biomedical Research in Sepsis (BioSepsis), Instituto de Investigación Biomédica de Salamanca, Gerencia Regional de Salud de Castilla y León, Salamanca, Spain.
  • Motos A; Centro de Investigación Biomédica en Red en Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain; Department of Pulmonology, Hospital Clinic de Barcelona, Institut D Investigacions August Pi I Sunyer (IDIBAPS), Universidad de Barcelona, Barcelona, Spain.
  • Resino S; Centro de Investigación Biomédica en Red en Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain; Viral Infection and Immunity Unit, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, Spain.
  • Tamayo L; Centro de Investigación Biomédica en Red en Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain; Critical Care Medicine Service, Hospital Universitario Rio Hortega, Gerencia Regional de Salud de Castilla y León, Valladolid, Spain.
  • Ryan Murua P; Centro de Investigación Biomédica en Red en Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain; Internal Medicine Service, Hospital Infanta Leonor, Madrid, Spain.
  • Bustamante-Munguira E; Centro de Investigación Biomédica en Red en Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain; Critical Care Medicine Service, Hospital Clínico Universitario de Valladolid, Gerencia Regional de Salud de Castilla y León, Valladolid, Spain.
  • Gallego Curto E; Centro de Investigación Biomédica en Red en Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain; Critical Care Medicine Service, Hospital San Pedro de Alcántara, Cáceres, Spain.
  • Úbeda-Iglesias A; Critical Care Medicine Service, Hospital Punta de Europa, Algeciras, Spain.
  • de la Torre MDC; Department of Intensive Care Medicine, Hospital de Mataró, Mataró, Spain.
  • Estella Á; Intensive Care Unit, Hospital Universitario de Jerez, Departamento de Medicina Universidad de Cádiz, INiBICA, Cádiz, Spain.
  • Campos-Fernández S; Critical Care Medicine Service, Hospital Universitario Marqués de Valdecilla, Santander, Spain.
  • Martínez Varela I; Critical Care Department, Hospital Universitario Lucus Augustí, Lugo, Spain.
  • Pérez-García F; Centro de Investigación Biomédica en Red en Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain; Clinical Microbiology Service, Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Spain; Biomedicine and Biotechnology Department, Faculty of Medicine, Univer
  • Socias L; Intensive Care Unit, Hospital Son Llàtzer, Palma, Spain.
  • López Messa J; Critical Care Medicine Service, Complejo Asistencial Universitario de Palencia, Palencia, Spain.
  • Vidal-Cortés P; Intensive Care Unit, Complejo Hospitalario Universitario de Ourense, Ourense, Spain.
  • Sagredo Meneses V; Critical Care Medicine Service, Complejo Asistencial de Salamanca, Salamanca, Spain.
  • González-Rivera M; Clinical Biochemistry Service, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
  • Carbonell N; Intensive Care Unit, Hospital Clínico Universitario de Valencia, Valencia, Spain.
  • de Gonzalo-Calvo D; Centro de Investigación Biomédica en Red en Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain; Translational Research in Respiratory Medicine, University Hospital Arnau de Vilanova and Santa Maria, Lleida, Spain.
  • Martín Delgado MC; Intensive Care Unit, Hospital Universitario de Torrejón, Torrejón, Spain.
  • Valdivia LJ; Critical Care Medicine Service, Hospital Universitario de León, León, Spain.
  • Martín-López C; Critical Care Medicine Service, Hospital General de Segovia, Segovia, Spain.
  • Jorge García RN; Intensive Care Department, Hospital Nuestra Señora de Gracia, Zaragoza, Spain.
  • Maseda E; Anesthesiology and Reanimation Service, Hospital Universitario de la Paz, Madrid, Spain.
  • Loza-Vázquez A; Critical Care Medicine Service, Hospital Universitario Nuestra Señora de Valme, Sevilla, Spain.
  • Kelvin DJ; Department of Microbiology and Immunology, Faculty of Medicine, Canadian Center for Vaccinology, Dalhousie University, Halifax, NS, Canada; Laboratory of Immunity, Shantou University Medical College, Shantou, Guangdong, China.
  • Barbé F; Centro de Investigación Biomédica en Red en Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain; Translational Research in Respiratory Medicine, University Hospital Arnau de Vilanova and Santa Maria, Lleida, Spain.
  • Torres A; Centro de Investigación Biomédica en Red en Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain; Department of Pulmonology, Hospital Clinic de Barcelona, Institut D Investigacions August Pi I Sunyer (IDIBAPS), Universidad de Barcelona, Barcelona, Spain.
Lancet Microbe ; 4(6): e431-e441, 2023 06.
Article en En | MEDLINE | ID: mdl-37116517
ABSTRACT

BACKGROUND:

The contribution of the virus to the pathogenesis of severe COVID-19 is still unclear. We aimed to evaluate associations between viral RNA load in plasma and host response, complications, and deaths in critically ill patients with COVID-19.

METHODS:

We did a prospective cohort study across 23 hospitals in Spain. We included patients aged 18 years or older with laboratory-confirmed SARS-CoV-2 infection who were admitted to an intensive care unit between March 16, 2020, and Feb 27, 2021. RNA of the SARS-CoV-2 nucleocapsid region 1 (N1) was quantified in plasma samples collected from patients in the first 48 h following admission, using digital PCR. Patients were grouped on the basis of N1 quantity VIR-N1-Zero (<1 N1 copies per mL), VIR-N1-Low (1-2747 N1 copies per mL), and VIR-N1-Storm (>2747 N1 copies per mL). The primary outcome was all-cause death within 90 days after admission. We evaluated odds ratios (ORs) for the primary outcome between groups using a logistic regression analysis.

FINDINGS:

1068 patients met the inclusion criteria, of whom 117 had insufficient plasma samples and 115 had key information missing. 836 patients were included in the analysis, of whom 403 (48%) were in the VIR-N1-Low group, 283 (34%) were in the VIR-N1-Storm group, and 150 (18%) were in the VIR-N1-Zero group. Overall, patients in the VIR-N1-Storm group had the most severe disease 266 (94%) of 283 patients received invasive mechanical ventilation (IMV), 116 (41%) developed acute kidney injury, 180 (65%) had secondary infections, and 148 (52%) died within 90 days. Patients in the VIR-N1-Zero group had the least severe disease 81 (54%) of 150 received IMV, 34 (23%) developed acute kidney injury, 47 (32%) had secondary infections, and 26 (17%) died within 90 days (OR for death 0·30, 95% CI 0·16-0·55; p<0·0001, compared with the VIR-N1-Storm group). 106 (26%) of 403 patients in the VIR-N1-Low group died within 90 days (OR for death 0·39, 95% CI 0·26-0·57; p<0·0001, compared with the VIR-N1-Storm group).

INTERPRETATION:

The presence of a so-called viral storm is associated with increased all-cause death in patients admitted to the intensive care unit with severe COVID-19. Preventing this viral storm could help to reduce poor outcomes. Viral storm could be an enrichment marker for treatment with antivirals or purification devices to remove viral components from the blood.

FUNDING:

Instituto de Salud Carlos III, Canadian Institutes of Health Research, Li Ka-Shing Foundation, Research Nova Scotia, and European Society of Clinical Microbiology and Infectious Diseases. TRANSLATION For the Spanish translation of the abstract see Supplementary Materials section.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Lesión Renal Aguda / Coinfección / COVID-19 Tipo de estudio: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Límite: Humans País/Región como asunto: America do norte / Europa Idioma: En Revista: Lancet Microbe Año: 2023 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Lesión Renal Aguda / Coinfección / COVID-19 Tipo de estudio: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Límite: Humans País/Región como asunto: America do norte / Europa Idioma: En Revista: Lancet Microbe Año: 2023 Tipo del documento: Article